Data compiled by Redley Lamar · ChainSifter Intelligence
9Suppliers
13Customers
3Debt Items
20Related Chains
Source-Backed Evidence Depth
Evofem Biosciences, Inc. (EVFM) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
25Total relationships
3Distinct source URLs
8High confidence
0.768Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Evofem Biosciences, Inc. Suppliers
Ticker
Name
Confidence
Evidence
CLOVIS-DAVIS-PHARMACEUTICALS-LLC
CLOVIS-DAVIS-PHARMACEUTICALS-LLC
92%
Under the distributorship agreement, Clovis Davis will lead the distribution, promotion, marketing, and sales of SOLOSEC within the Territory.
WINDTREE-THERAPEUTICS-INC
WINDTREE-THERAPEUTICS-INC
92%
On March 20, 2025, Windtree Therapeutics, Inc. (Windtree) and the Company entered into a License and Supply Agreement, as amended on March 28, 2025 (collectively, the Windtree License and Supply Agre…
Reciprocal relationship from WINT graph: Reciprocal relationship from EVFM graph: Reciprocal relationship from WINT graph: we will act as the supplier to Evofem of its Phexxi® product outside of the …
umber of sales employees; this negatively impacted our ability to maintain our sales and marketing capabilities. Any failure or future delay in the timely development of our internal commercializatio…
Reciprocal relationship from JNJ graph: Reciprocal relationship from EVFM graph: umber of sales employees; this negatively impacted our ability to maintain our sales and marketing capabilities. Any f…
Reciprocal relationship from MRK graph: Reciprocal relationship from EVFM graph: umber of sales employees; this negatively impacted our ability to maintain our sales and marketing capabilities. Any f…
umber of sales employees; this negatively impacted our ability to maintain our sales and marketing capabilities. Any failure or future delay in the timely development of our internal commercializatio…
n such a competitor or third party would then be able to introduce a competitive generic product onto the market once any available regulatory exclusivity has expired. The FDA has broad discretion in…
Reciprocal relationship from ORANY graph: Reciprocal relationship from EVFM graph: Reciprocal relationship from ORANY graph: Reciprocal relationship from EVFM graph: n such a competitor or third part…
Evofem Biosciences, Inc. Customers
Ticker
Name
Confidence
Evidence
WINTW
WINDTREE THERAPEUTICS INC C/WTS
92%
Reciprocal relationship from WINTW graph: Reciprocal relationship from EVFM graph: Reciprocal relationship from WINTW graph: Reciprocal relationship from EVFM graph: Reciprocal relationship from WINT…
Reciprocal relationship from JNJ graph: Reciprocal relationship from EVFM graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from EVFM graph: Reciprocal relationship from JNJ grap…
umber of sales employees; this negatively impacted our ability to maintain our sales and marketing capabilities. Any failure or future delay in the timely development of our internal commercializatio…
Reciprocal relationship from MRK graph: Reciprocal relationship from EVFM graph: Reciprocal relationship from MRK graph: Reciprocal relationship from EVFM graph: Reciprocal relationship from MRK grap…
umber of sales employees; this negatively impacted our ability to maintain our sales and marketing capabilities. Any failure or future delay in the timely development of our internal commercializatio…
n such a competitor or third party would then be able to introduce a competitive generic product onto the market once any available regulatory exclusivity has expired. The FDA has broad discretion in…
Reciprocal relationship from ORANY graph: Reciprocal relationship from EVFM graph: n such a competitor or third party would then be able to introduce a competitive generic product onto the market onc…
Reciprocal relationship from WINT graph: Reciprocal relationship from EVFM graph: ial in each of the three months ended March 31, 2026 and 2025. As of March 31, 2026, $ 0.1 million and $ 1.1 million …
ial in each of the three months ended March 31, 2026 and 2025. As of March 31, 2026, $ 0.1 million and $ 1.1 million for the future payments that could become due related to the SOLOSEC acquisition, …
CAPITAL-RESOURCES
CAPITAL-RESOURCES
62%
erentiator. Non-compliance to a multi-day metronidazole regimen is a contributing factor to persistent Trich or BV; both ACOG and the CDC no longer recommend single dose metronidazole to treat Trich …
FUTURE-PAK-LLC
FUTURE-PAK-LLC
62%
organizations) are able to purchase products at a price discounted below WAC. The difference between the government or covered entity purchase price and the wholesale distributor purchase price of WA…
OTC-MARKETS-GROUP
OTC-MARKETS-GROUP
62%
QB Listing Standards, Section 4.1, to regain compliance with the Minimum Bid Price Requirement the Company’s closing bid price was required to be equal to or greater than $ 0.01 for ten consecutive t…
Evofem Biosciences, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
EVFM-DEBT
Debt stack $4.0M
90%
Market cache reports total debt of $4.0M.
EVFM-DEBT-9389
Warrants outstanding: 263062097
90%
xbrl warrant detail from xbrl 2026-03-31.
EVFM-DEBT-9390
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2024-12-31.
Evofem Biosciences, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Evofem Biosciences, Inc..
Evofem Biosciences, Inc. Ownership
No ownership data on recordNo major institutional ownership relationships found in our database for Evofem Biosciences, Inc..
Evofem Biosciences, Inc. Extended Supply Chain Network
